The European Commission is currently receiving new treatment for broken pancreas cancer: patients live on average 12.4 months longer
The European Commission has approved Daraxonrasib twice a day, a new treatment for broken pancreas cancer.The authorisation was granted through an accelerated procedure because there are few other treatments available to this patient group.
IntelMap indexes open-source reporting. This page identifies what a source reported; it does not independently confirm the claim.
2 reports · 2 sources
Het Laatste NieuwsThe European Commission is currently receiving new treatment for broken pancreas cancer: patients live on average 12.4 months longerHet Laatste NieuwsThe European Commission is currently receiving new treatment for broken pancreas cancer: patients live on average 12.4 months longer9 recorded states
Signal first indexedP1 · 68% quality · 1 source
Corroboration 1→2 sources · quality 68→72P1 · 72% quality · 2 sources
Quality 72→76P1 · 76% quality · 2 sources
Quality 76→80P1 · 80% quality · 2 sources
Quality 80→84P1 · 84% quality · 2 sources
Quality 84→88P1 · 88% quality · 2 sources
Quality 88→92P1 · 92% quality · 2 sources
Quality 92→96P1 · 96% quality · 2 sources
Quality 96→99P1 · 99% quality · 2 sources